Suchergebnisse
Katalog
Mehr
Suchmaske
Suchergebnisse einschränken oder erweitern
Aktive Suchfilter
Weniger Treffer
Art der Quelle
Thema
- pharmaceutical industry 25 Treffer
- corporate profits 15 Treffer
- business cycles 14 Treffer
- business finance 14 Treffer
- corporate growth 14 Treffer
-
45 weitere Werte:
- financial performance 14 Treffer
- industrial location 14 Treffer
- corporations 11 Treffer
- therapeutics 7 Treffer
- clinical trials 6 Treffer
- drug development 6 Treffer
- united states. food & drug administration 5 Treffer
- business turnover 4 Treffer
- generic drugs 4 Treffer
- mental depression 4 Treffer
- over-the-counter markets 4 Treffer
- revenue 4 Treffer
- central nervous system diseases 3 Treffer
- drug approval 3 Treffer
- drugs 3 Treffer
- pain management 3 Treffer
- placebos 3 Treffer
- swot analysis 3 Treffer
- fiscal year 2 Treffer
- medical research 2 Treffer
- pfizer inc. 2 Treffer
- sun pharmaceuticals llc 2 Treffer
- ticker symbols 2 Treffer
- alzheimer's disease treatment 1 Treffer
- american pain society 1 Treffer
- american psychiatric association 1 Treffer
- analgesics 1 Treffer
- annual meetings 1 Treffer
- antidepressants 1 Treffer
- antihypertensive agents 1 Treffer
- antipsychotic agents 1 Treffer
- anxiety 1 Treffer
- astrazeneca plc 1 Treffer
- aurobindo pharma ltd. 1 Treffer
- baxter international inc. 1 Treffer
- biovail corp. 1 Treffer
- bipolar disorder 1 Treffer
- business enterprises 1 Treffer
- business expansion 1 Treffer
- business partnerships 1 Treffer
- business revenue 1 Treffer
- centocor inc. 1 Treffer
- central nervous system depressants 1 Treffer
- clinical data inc. 1 Treffer
- clinical drug trials 1 Treffer
Publikation
Sprache
Geographischer Bezug
Inhaltsanbieter
39 Treffer
-
In: PharmaWatch: CNS, Jg. 11 (2012-06-01), Heft 6, S. 24-25reportZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2013-04-01, S. 1-8unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2013-02-01, S. 1-8unknownZugriff:
-
In: PharmaWatch: CNS, Jg. 11 (2012-09-01), Heft 9, S. 23-27reportZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2012-06-01, S. 1-8unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2012-05-01, S. 1-8unknownZugriff:
-
In: PharmaWatch: CNS, Jg. 10 (2011-04-01), Heft 4, S. 8-12reportZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-03-01, S. 4-4unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-03-01, S. 4-4unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-02-01, S. 4-4unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-02-01, S. 4-4unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2005-11-01, S. 4-4unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2005-11-01, S. 4-4unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-03-01, S. 5-9unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-03-01, S. 1-10unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-02-01, S. 5-13unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2006-02-01, S. 1-14unknownZugriff:
-
In: Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies, 2005-11-01, S. 1-17reportZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2005-11-01, S. 5-8unknownZugriff:
-
In: Forest Laboratories, Inc. SWOT Analysis, 2005-11-01, S. 1-9unknownZugriff: